Phase II trial of VEGFR2 inhibitor apatinib for metastatic sarcoma: focus on efficacy and safety
Cancer: Starving sarcomas into submission A drug that inhibits blood vessel growth offers a potentially promising treatment for a class of tumors with a poor prognosis. Sarcomas form in bone and connective tissue, and patients with advanced disease have a five-year survival rate of less than 10%. Re...
| Main Authors: | , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Publishing Group
2019-02-01
|
| Series: | Experimental and Molecular Medicine |
| Online Access: | https://doi.org/10.1038/s12276-019-0221-7 |
| _version_ | 1818428504710053888 |
|---|---|
| author | Zhichao Liao Feng Li Chao Zhang Lei Zhu Yehui Shi Gang Zhao Xu Bai Shafat Hassan Xinyue Liu Ting Li Peipei Xing Jun Zhao Jin Zhang Ruwei Xing Sheng Teng Yun Yang Kexin Chen Jilong Yang |
| author_facet | Zhichao Liao Feng Li Chao Zhang Lei Zhu Yehui Shi Gang Zhao Xu Bai Shafat Hassan Xinyue Liu Ting Li Peipei Xing Jun Zhao Jin Zhang Ruwei Xing Sheng Teng Yun Yang Kexin Chen Jilong Yang |
| author_sort | Zhichao Liao |
| collection | DOAJ |
| description | Cancer: Starving sarcomas into submission A drug that inhibits blood vessel growth offers a potentially promising treatment for a class of tumors with a poor prognosis. Sarcomas form in bone and connective tissue, and patients with advanced disease have a five-year survival rate of less than 10%. Researchers led by Jilong Yang of the Tainjin Medical University Cancer Institute & Hospital in China tested apatanib, a drug that starves tumors by preventing blood vessel development, in late-stage sarcoma patients. Strikingly, 15% of the patients experienced tumor reduction after treatment, and more than half overall achieved at least partial disease control. Adverse events were generally mild, but Yang and colleagues observed that patients who experienced certain side-effects achieved a greater survival benefit from treatment. These results support further investigation of this drug, and offer hints of possible biomarkers to predict response. |
| first_indexed | 2024-12-14T15:02:41Z |
| format | Article |
| id | doaj.art-47373e8785a54132934e2a266ec18ce4 |
| institution | Directory Open Access Journal |
| issn | 1226-3613 2092-6413 |
| language | English |
| last_indexed | 2024-12-14T15:02:41Z |
| publishDate | 2019-02-01 |
| publisher | Nature Publishing Group |
| record_format | Article |
| series | Experimental and Molecular Medicine |
| spelling | doaj.art-47373e8785a54132934e2a266ec18ce42022-12-21T22:56:46ZengNature Publishing GroupExperimental and Molecular Medicine1226-36132092-64132019-02-0151311110.1038/s12276-019-0221-7Phase II trial of VEGFR2 inhibitor apatinib for metastatic sarcoma: focus on efficacy and safetyZhichao Liao0Feng Li1Chao Zhang2Lei Zhu3Yehui Shi4Gang Zhao5Xu Bai6Shafat Hassan7Xinyue Liu8Ting Li9Peipei Xing10Jun Zhao11Jin Zhang12Ruwei Xing13Sheng Teng14Yun Yang15Kexin Chen16Jilong Yang17Departments of Bone and Soft Tissue Tumor, Tianjin Medical University Cancer Institute & HospitalDepartments of Bone and Soft Tissue Tumor, Tianjin Medical University Cancer Institute & HospitalDepartments of Bone and Soft Tissue Tumor, Tianjin Medical University Cancer Institute & HospitalNational Clinical Research Center of Cancer, Tianjin Medical University Cancer Institute & HospitalNational Clinical Research Center of Cancer, Tianjin Medical University Cancer Institute & HospitalNational Clinical Research Center of Cancer, Tianjin Medical University Cancer Institute & HospitalNational Clinical Research Center of Cancer, Tianjin Medical University Cancer Institute & HospitalDepartments of Bone and Soft Tissue Tumor, Tianjin Medical University Cancer Institute & HospitalDepartments of Bone and Soft Tissue Tumor, Tianjin Medical University Cancer Institute & HospitalDepartments of Bone and Soft Tissue Tumor, Tianjin Medical University Cancer Institute & HospitalDepartments of Bone and Soft Tissue Tumor, Tianjin Medical University Cancer Institute & HospitalDepartments of Bone and Soft Tissue Tumor, Tianjin Medical University Cancer Institute & HospitalDepartments of Bone and Soft Tissue Tumor, Tianjin Medical University Cancer Institute & HospitalDepartments of Bone and Soft Tissue Tumor, Tianjin Medical University Cancer Institute & HospitalDepartments of Bone and Soft Tissue Tumor, Tianjin Medical University Cancer Institute & HospitalDepartments of Bone and Soft Tissue Tumor, Tianjin Medical University Cancer Institute & HospitalNational Clinical Research Center of Cancer, Tianjin Medical University Cancer Institute & HospitalDepartments of Bone and Soft Tissue Tumor, Tianjin Medical University Cancer Institute & HospitalCancer: Starving sarcomas into submission A drug that inhibits blood vessel growth offers a potentially promising treatment for a class of tumors with a poor prognosis. Sarcomas form in bone and connective tissue, and patients with advanced disease have a five-year survival rate of less than 10%. Researchers led by Jilong Yang of the Tainjin Medical University Cancer Institute & Hospital in China tested apatanib, a drug that starves tumors by preventing blood vessel development, in late-stage sarcoma patients. Strikingly, 15% of the patients experienced tumor reduction after treatment, and more than half overall achieved at least partial disease control. Adverse events were generally mild, but Yang and colleagues observed that patients who experienced certain side-effects achieved a greater survival benefit from treatment. These results support further investigation of this drug, and offer hints of possible biomarkers to predict response.https://doi.org/10.1038/s12276-019-0221-7 |
| spellingShingle | Zhichao Liao Feng Li Chao Zhang Lei Zhu Yehui Shi Gang Zhao Xu Bai Shafat Hassan Xinyue Liu Ting Li Peipei Xing Jun Zhao Jin Zhang Ruwei Xing Sheng Teng Yun Yang Kexin Chen Jilong Yang Phase II trial of VEGFR2 inhibitor apatinib for metastatic sarcoma: focus on efficacy and safety Experimental and Molecular Medicine |
| title | Phase II trial of VEGFR2 inhibitor apatinib for metastatic sarcoma: focus on efficacy and safety |
| title_full | Phase II trial of VEGFR2 inhibitor apatinib for metastatic sarcoma: focus on efficacy and safety |
| title_fullStr | Phase II trial of VEGFR2 inhibitor apatinib for metastatic sarcoma: focus on efficacy and safety |
| title_full_unstemmed | Phase II trial of VEGFR2 inhibitor apatinib for metastatic sarcoma: focus on efficacy and safety |
| title_short | Phase II trial of VEGFR2 inhibitor apatinib for metastatic sarcoma: focus on efficacy and safety |
| title_sort | phase ii trial of vegfr2 inhibitor apatinib for metastatic sarcoma focus on efficacy and safety |
| url | https://doi.org/10.1038/s12276-019-0221-7 |
| work_keys_str_mv | AT zhichaoliao phaseiitrialofvegfr2inhibitorapatinibformetastaticsarcomafocusonefficacyandsafety AT fengli phaseiitrialofvegfr2inhibitorapatinibformetastaticsarcomafocusonefficacyandsafety AT chaozhang phaseiitrialofvegfr2inhibitorapatinibformetastaticsarcomafocusonefficacyandsafety AT leizhu phaseiitrialofvegfr2inhibitorapatinibformetastaticsarcomafocusonefficacyandsafety AT yehuishi phaseiitrialofvegfr2inhibitorapatinibformetastaticsarcomafocusonefficacyandsafety AT gangzhao phaseiitrialofvegfr2inhibitorapatinibformetastaticsarcomafocusonefficacyandsafety AT xubai phaseiitrialofvegfr2inhibitorapatinibformetastaticsarcomafocusonefficacyandsafety AT shafathassan phaseiitrialofvegfr2inhibitorapatinibformetastaticsarcomafocusonefficacyandsafety AT xinyueliu phaseiitrialofvegfr2inhibitorapatinibformetastaticsarcomafocusonefficacyandsafety AT tingli phaseiitrialofvegfr2inhibitorapatinibformetastaticsarcomafocusonefficacyandsafety AT peipeixing phaseiitrialofvegfr2inhibitorapatinibformetastaticsarcomafocusonefficacyandsafety AT junzhao phaseiitrialofvegfr2inhibitorapatinibformetastaticsarcomafocusonefficacyandsafety AT jinzhang phaseiitrialofvegfr2inhibitorapatinibformetastaticsarcomafocusonefficacyandsafety AT ruweixing phaseiitrialofvegfr2inhibitorapatinibformetastaticsarcomafocusonefficacyandsafety AT shengteng phaseiitrialofvegfr2inhibitorapatinibformetastaticsarcomafocusonefficacyandsafety AT yunyang phaseiitrialofvegfr2inhibitorapatinibformetastaticsarcomafocusonefficacyandsafety AT kexinchen phaseiitrialofvegfr2inhibitorapatinibformetastaticsarcomafocusonefficacyandsafety AT jilongyang phaseiitrialofvegfr2inhibitorapatinibformetastaticsarcomafocusonefficacyandsafety |